2020년 Business Management SL IA 입니다. (7점)

1. Introduction

Roche is one of the world’s largest pharmaceutical companies that was established in 1896, in Switzerland. Roche was founded to serve innovative machines and diagnostic tests to patients throughout the world. It develops biologic medical products and delivers targeted therapies in oncology, neuroscience, infectious diseases, and so on. Roche has led cancer research and treatment for over 50 years including medicines for breast, skin, colon, ovarian, and others. Roche expanded its business by building a network of agents and subsidiaries in Europe and overseas mainly investing in New York. Currently, Roche has around 90,000 people working in more than a hundred countries with its annual investment around 9 billion Swiss francs that is to induce research and development (Roche). Successful investment in R&D would bring greater financial outcome than the amount that was invested. However, R&D heavily challenges the company because billions of dollars spent on the project would turn into failures, and failed projects would even threaten the values of the brand. Since this investment in R&D would bring great benefits to the company while also bringing risks, I pose the research question, “How rational is Roche’s investment in R&D in personalized cancer treatments?”